Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
A Feasibility Study of Alendronate as Treatment for Osteonecrosis in Adults With Sickle Cell Disease
Open to underrepresented populationsRace/ethnicity-specific condition
Phase
PHASE2
Enrollment
50 (est.)
Age range
— to —
Sex
ALL
Summary
A prospective, single-arm study of oral alendronate in adults with sickle cell disease and osteonecrosis, enrolling patients followed at UC Davis. (Dates were not available in the source record consulted and are pending a full API sync.)
Conditions studied
Avascular NecrosisIschemic NecrosisOsteonecrosisSickle Cell AnemiaSickle Cell Disease
Sign-up window
Check back for sign-up dates
Sponsors
University of California, DavisLead
Study locations
University of California Davis Medical Center
Sacramento, California
Site contact being verified